All In MedTech

FDA Clearance Tracker · P840064-S062

VISCOAT OPHTHALMIC VISCOSURGICAL DEVICE; DUOVISC OPHTHALMIC VISCOSURGICAL DEVICE (WITH PROVISC IN LATEX-FREE PACK)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 31, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 31, 2017

Approved

Time to decision

467 days

Received Jul 21, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P840064-S062
Device name
VISCOAT OPHTHALMIC VISCOSURGICAL DEVICE; DUOVISC OPHTHALMIC VISCOSURGICAL DEVICE (WITH PROVISC IN LATEX-FREE PACK)
Applicant location
Fort Worth, TX
Received
Jul 21, 2016
Decided
Oct 31, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P840064

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site change located at Lifecore Biomedical, LLC., 3515 Lyman Boulevard, Chaska, Minnesota, USA, and Lifecore Biomedical, LLC, 1245 Lakeview Drive, Chaska, Minnesota, USA.

Source documents

Other decisions for Alcon Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.